Ithuthukiswe yi-Ascentage Pharma ngosizo oluvela kuhlelo lweNational Major New Drug Discovery and Manufacturing, i-olverembatinib iyisidakamizwa esingaba sezingeni eliphezulu esizothengiswa ngokubambisana emakethe yaseChina yi-Innovent kanye ne-Ascentage Pharma, ukuze kuzuze iziguli eziningi imindeni. Njengoba isizukulwane sokuqala sesithathu sase-China i-BCL-ABL TKI ithuthukiswe ukwelashwa kwe-CML engazweli i-TKI, le mvume igcwalisa igebe elibalulekile lokwelashwa ku-T315I-mutant CML, futhi iphawula ingqopha-mlando ebonisa ukuthi i-Ascentage Pharma ingene ngempumelelo esigabeni sokuhweba.
Lokhu kugunyazwa kwe-olverembatinib kusekelwe emiphumeleni yocwaningo lweSigaba II esibalulekile - ucwaningo lwe-HQP1351CC201 kanye nocwaningo lwe-HQP1351CC202. Le miphumela ibonise ukuthi i-olverembatinib iyasebenza futhi ibekezelelwa kahle ezigulini ezine-CML-CP ne-CML-AP, futhi amathuba nokujula kwempendulo yomtholampilo kulindeleke ukuthi kukhule ngokuhamba kwesikhathi sokwelashwa.
I-CML iyisifo se-hematological samaseli amhlophe egazi. Ukwethulwa kwama-BCR-ABL TKIs kuthuthukise kakhulu ukuphathwa komtholampilo kwe-CML. Nokho, ukutholwa kokumelana nama-TKI kuseyinselelo enkulu ekwelashweni kwe-CML. Ukuguqulwa kwe-BCR-ABL kwe-tyrosine kinase kumelela indlela eyinhloko yokumelana nomuthi okutholiwe; I-T315I, okuwushintsho oluvame kakhulu olumelana nomuthi, kwenzeka cishe ku-25% weziguli ezine-CML engazweli emthini. Iziguli ezine-T315I-mutant CML azikwazi ukumelana nakho kokubili isizukulwane sokuqala nesesibili se-BCR-ABL inhibitors, yingakho zethula isidingo esiphuthumayo sezokwelapha esingahlangabeziwe sokwelashwa okusebenzayo.